ARDS, Human Clinical Trial
— PROVEOfficial title:
Enhanced Lung Protective Ventilation With Extracorporeal CO2 Removal During Acute Respiratory Distress Syndrome
Verified date | December 2023 |
Source | Hôpital Européen Marseille |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Acute Respiratory Distress Syndrome (ARDS) is associated with a mortality rate of 30 - 45 % and required invasive mechanical ventilation (MV) in almost 85 % of patients[1]. During controlled MV, driving pressure (i.e., the difference between end-inspiratory and end-expiratory airway pressure) depends of both tidal volume and respiratory system compliance. Either excessive tidal volume or reduced lung aeration may increase the driving pressure. ARDS patients receiving tidal volume of 6 ml/kg predicted body weight (PBW) and having a day-1 driving pressure ≥ 14 cmH2O have an increased risk of death in the hospital[2]. Seemly, in the LUNG SAFE observational cohort, ARDS patients having a day-1 driving pressure < 11 cmH2O had the lowest risk of death in the hospital[1]. Hence, driving pressure acts as a major contributor of mortality in ARDS, and probably reflects excessive regional lung distension resulting in pro-inflammatory and fibrotic biological processes. Whether decreasing the driving pressure by an intervention change mortality remains an hypothesis; but one of means is to decrease the tidal volume from 6 to 4 ml/ kg predicted body weight (PBW). However, this strategy promotes hypercarbia, at constant respiratory rate, by decreasing the alveolar ventilation. In this setting, implementing an extracorporeal CO2 removal (ECCO2R) therapy prevents from hypercarbia. A number of low-flow ECCO2R devices are now available and some of those use renal replacement therapy (RRT) platform. The investigators previously reported that combining a membrane oxygenator (0.65 m²) within a hemofiltration circuit provides efficacious low flow ECCO2R and blood purification in patients presenting with both ARDS and Acute Kidney injury[3]. This study aims to investigate the efficacy of an original ECCO2R system combining a 0.67 m² membrane oxygenator (Lilliput 2, SORIN) inserted within a specific circuit (HP-X, BAXTER) and mounted on a RRT monitor (PrismafleX, BAXTER). Such a therapy only aims to provide decarboxylation but not blood purification and has the huge advantage to be potentially implemented in most ICUs without requiring a specific ECCO2R device. The study will consist in three periods: - The first period will address the efficacy of this original ECCO2R system at tidal volume of 6 and 4 ml/kg PBW using an off-on-off design. - The second part will investigate the effect of varying the sweep gas flow (0-2-4-6-8-10 l/min) and the mixture of the sweep gas (Air/O2) on the CO2 removal rate. - The third part will compare three ventilatory strategies applied in a crossover design: 1. Minimal distension: Tidal volume 4 ml/kg PBW and positive end-expiratory pressure (PEEP) based on the ARDSNet PEEP/FiO2 table (ARMA). 2. Maximal recruitment: 4 ml/kg PBW and PEEP adjusted to maintain a plateau pressure between 23 - 25 cmH2O. 3. Standard: Tidal volume 6 ml/kg and PEEP based on the ARDSNet PEEP/FiO2 table (ARMA).
Status | Terminated |
Enrollment | 3 |
Est. completion date | December 5, 2023 |
Est. primary completion date | December 5, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - ARDS moderate or severe (Berlin criteria) - Onset < 48 h - Driving pressure = 11 cmH2O Exclusion Criteria: - Lack of consent or social protection - Chronic respiratory failure (requiring Oxygen or NIPPV) - Severe hypoxemia: PaO2/FIO2 < 80 with PEEP = 18 cmH2O AND FIO2= 1 - Acute Renal Failure requiring RRT - DNR order or death expected within the next 72 hours - Planned surgery or transport out-of-ICU expected within the next 72 hours - Heparin allergy - Contraindication to jugular vein catheterization - Intracranial Hypertension |
Country | Name | City | State |
---|---|---|---|
France | Service de REANIMATION, HOPITAL EUROPEEN MARSEILLE | Marseille |
Lead Sponsor | Collaborator |
---|---|
Hôpital Européen Marseille |
France,
Allardet-Servent J, Castanier M, Signouret T, Soundaravelou R, Lepidi A, Seghboyan JM. Safety and Efficacy of Combined Extracorporeal CO2 Removal and Renal Replacement Therapy in Patients With Acute Respiratory Distress Syndrome and Acute Kidney Injury: T — View Citation
Amato MB, Meade MO, Slutsky AS, Brochard L, Costa EL, Schoenfeld DA, Stewart TE, Briel M, Talmor D, Mercat A, Richard JC, Carvalho CR, Brower RG. Driving pressure and survival in the acute respiratory distress syndrome. N Engl J Med. 2015 Feb 19;372(8):74 — View Citation
Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, Gattinoni L, van Haren F, Larsson A, McAuley DF, Ranieri M, Rubenfeld G, Thompson BT, Wrigge H, Slutsky AS, Pesenti A; LUNG SAFE Investigators; ESICM Trials Group. Epidemiology, Patterns of Care, — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Plasma Free Hemoglobin | serum samples | every 24 hours, up to 72 hours. | |
Other | Haptoglobin | serum samples | every 24 hours, up to 72 hours. | |
Other | Lacticodéshydrogenase (LDH) | serum samples | every 24 hours, up to 72 hours. | |
Other | schizocytes | serum samples | every 24 hours, up to 72 hours. | |
Other | Bilirubin | serum samples | every 24 hours, up to 72 hours. | |
Primary | Change in PaCO2 | 20 % decrease in PaCO2 after initiation of ECCO2R at tidal volume of 4 ml/kg PBW (as compared to 4 ml/kg without ECCO2R) | 15 minutes after initiation of ECCO2R at tidal volume of 4 ml/kg PBW. | |
Secondary | PaCO2 | Arterial blood gas analyser (RAPIDPoint 500) | each 15 minutes up to the third hour (Part I and II of the study). In the third part, measurement at baseline and at 1 hour and at 22 hours into each arm. | |
Secondary | CO2 removal rate | Using measurements from both the blood side and the gas side (two methods) | each 15 minutes up to the third hour (Part I and II of the study). In the third part, measurement at baseline and at 1 hour and at 22 hours into each arm. | |
Secondary | Transpulmonary pressure and work of breathing | Using an oesophageal balloon catheter (NutriVent catheter) and a dedicated monitor (FluxMed, MBMed) | each 15 minutes up to the third hour (Part I and II of the study). In the third part, measurement at baseline and at 1 hour and at 22 hours into each arm. | |
Secondary | Regional tidal ventilation | Using an Electrical Impedance Tomography device (BB², Swisstom) | each 15 minutes up to the third hour (Part I and II of the study). In the third part, measurement at baseline and at 1 hour and at 22 hours into each arm. | |
Secondary | End-expiratory Lung Volume | Using the nitrogen wash-in wash-out method (Engstrom GE) | each 15 minutes up to the third hour (Part I and II of the study). In the third part, measurement at baseline and at 1 hour and at 22 hours into each arm. | |
Secondary | Plasma Cytokines | Using Elisa custom kit (Qiagen) from plasma samples | Only in the third part, measurement at baseline and at 1 hour and at 22 hours into each arm. | |
Secondary | Pulmonary Cytokines | Using Elisa custom kit (Qiagen) from BAL samples | Only in the third part, measurement at baseline and at 1 hour and at 22 hours into each arm. | |
Secondary | Type III Procollagen | Using both RIA and Elisa methods from plasma and BAL samples | Only in the third part, measurement at baseline and at 1 hour and at 22 hours into each arm. | |
Secondary | Pulmonary Inflammatory and Fibrotic pathway | Using mRNA custom kit RT-PCR analysis (Qiagen) from BAL samples | Only in the third part, measurement at baseline and at 1 hour and at 22 hours into each arm. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06444750 -
Comparison of the Proteome in ICU Patients in Search for TRALI Biomarkers
|
||
Not yet recruiting |
NCT05306392 -
Effects of Induced Moderate Hypothermia on ARDS Patients Under Venovenous ExtraCorporeal Membrane Oxygenation
|
N/A | |
Terminated |
NCT04954014 -
Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients
|
Phase 2 | |
Completed |
NCT04719182 -
Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19
|
||
Completed |
NCT04274296 -
Advisory Lead ARDS Respirator Management
|
||
Recruiting |
NCT03215316 -
Screening Expiratory Flow Limitation by Flow-time Curve
|
N/A | |
Recruiting |
NCT04115514 -
Treatment of ARDS With Instilled T3
|
Phase 2 | |
Not yet recruiting |
NCT05061212 -
The Mechanism of Extracellular Vesicles Containing Mitochondrial DNA in ARDS Lung Injury Caused by Extrapulmonary Sepsis
|
||
Completed |
NCT05693051 -
Use of Prone Position Ventilation in Danish Patients With COVID-19 Induced Severe ARDS Treated With VV-ECMO
|
||
Not yet recruiting |
NCT04556864 -
Hemodynamic Impact on Critical Care Patients With Lung Damage Secondary to COVID-19
|
||
Recruiting |
NCT04174014 -
Optimal PEEP Titration Combining Transpulmonary Pressure Measurement and Electric Impedance Tomography
|
N/A | |
Enrolling by invitation |
NCT06164639 -
Potential Biomarkers for Reflux Aspiration-induced Lung Injury.
|
||
Terminated |
NCT05384379 -
Efficacy and Safety Evaluation of BZ371B in ARDS Patients
|
Early Phase 1 | |
Completed |
NCT04375735 -
London's Exogenous Surfactant Study for COVID19
|
Phase 1/Phase 2 | |
Completed |
NCT06224010 -
Respiratory Drive and Inspiratory Effort in COVID-19 Associated ARDS
|
||
Not yet recruiting |
NCT04530188 -
Effects of Sevoflurane on Extravascular Lung Water and Pulmonary Vascular Permeability in Patients With ARDS
|
Phase 3 | |
Completed |
NCT03405038 -
Prone Position Impact in ARDS Patients on the Incidence of Central Venous Catheter Colonization
|
||
Recruiting |
NCT05148026 -
Regional Citrate Anticoagulation for RRT During V-V ECMO
|
N/A | |
Recruiting |
NCT04390360 -
Smartphone Application for Initiation of Protective Ventilation. Clinical Impact of Instrumental Dead Space Reduction
|
N/A | |
Completed |
NCT06197256 -
Cardiac Dysfunction in Critically Ill Covid-19 Patients
|